MAIA Biotechnology Enters Into Clinical Master Supply Agreement With Roche For Future Studies Investigating Combination Of MAIA's THIO, Sequenced With Roche's CPI, Atezolizumab For Cancer Treatments

• Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.